Samsung Biologics CEO John Rim /Courtesy of Samsung BiologicsSamsung Biologics has appointed John Rim as its new president, embracing the second-generation leadership of its contract drug manufacturing business. Samsung Biologics held a board meeting on Wednesday and appointed the Korean American as its new head. The appointment was made effective immediately. Rim will continue to serve on the company's board as an inside director offering his in-depth industry experience and global background. Rim's appointment came after his predecessor Kim Tae-han resigned earlier this month, after leading the company since 2011 as a founding member.